The inhibitor sgi-201 targeting STAT3 effectively suppresses hyperglycemia-induced peritoneal fibrosis by inhibiting angiogenesis, macrophage infiltration, and HIF-1α expression. Here, STAT3 is linked to Peritoneal Fibrosis.